20 June 2013
Keywords: fda, accepts, gsk, coreg, cr, nda, review
Article | 20 March 2006
UK drug major GlaxoSmithKline says that the New Drug Application for its beta-blocker Coreg CR (carvedilol phosphate controlled-release
capsules), which ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
20 March 2006
19 June 2013
© 2013 thepharmaletter.com